The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Cited by
Sorted by citations
Items 401–500 of 1,003
Molecular pathogenesis of IDH mutations in gliomas
Ichimura, K. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0090-4 · Cited by 134
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing
Agarwal, S., Sharma, M. C., Jha, P., Pathak, P., Suri, V. S., Sarkar, C., Chosdol, K., Suri, A., Kale, S. S., Mahapatra, A. K., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not015 · Cited by 134
Deregulation of cell signaling in cancer
Giancotti, F. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.005 · Cited by 133
The mini-driver model of polygenic cancer evolution
Castro-Giner, F., Ratcliffe, P. J., & Tomlinson, I. P. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3999 · Cited by 133
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
How I treat pediatric acute myeloid leukemia
Rubnitz, J. E. (2012) · Blood · doi:10.1182/blood-2012-02-392506 · Cited by 132
Janin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 131
Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
Gaal, J., Burnichon, N., Korpershoek, E., Roncelin, I., Bertherat, J. Y., Plouin, P., de Krijger, R. R., Gimenez‐Roqueplo, A., & Dinjens, W. N. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2170 · Cited by 131
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 131
Global Profiling Strategies for Mapping Dysregulated Metabolic Pathways in Cancer
Benjamin, D. I., Cravatt, B. F., & Nomura, D. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.013 · Cited by 131
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 130
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
McNeer, N. A., Philip, J., Geiger, H. M., Ries, R. E., Lavallée, V., Walsh, M. F., Shah, M. J., Arora, K. S., Emde, A., Robine, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0402-3 · Cited by 130
Self-citationCardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 130
Gutmann, D. H., McLellan, M. D., Hussain, I., Wallis, J. W., Fulton, L., Fulton, R. S., Magrini, V. J., Demeter, R., Wylie, T., Kandoth, C., et al. (2012) · Genome Research · doi:10.1101/gr.142604.112 · Cited by 130
Self-citationClonal evolution of acute leukemia genomes
Jan, M., & Majeti, R. (2012) · Oncogene · doi:10.1038/onc.2012.48 · Cited by 129
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 129
Current findings for recurring mutations in acute myeloid leukemia
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-36 · Cited by 128
INTEGRATE: gene fusion discovery using whole genome and transcriptome dataPreprint
Zhang, J., White, N. M. A., Schmidt, H. K., Fulton, R. S., Tomlinson, C., Warren, W. C., Wilson, R. K., & Maher, C. A. (2015) · Genome Research · doi:10.1101/gr.186114.114 · Cited by 128
Self-citationZou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., & Gu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068782 · Cited by 127
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 127
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 126
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126
Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side
Prieto-Bermejo, R., Romo-González, M., Pérez‐Fernández, A., Ijurko, C., & Hernández‐Hernández, Á. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0797-0 · Cited by 126
Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression
Chen, J., & Du, B. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2796-0 · Cited by 126
Guan, Y., Li, G.-R., Wang, R., Yi, Y., Yang, L. M., Jiang, D., Zhang, X., & Peng, Y. (2012) · 癌症：英文版 · doi:10.5732/cjc.012.10216 · Cited by 125
Alterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Molecular therapy for acute myeloid leukaemia
Coombs, C. C., Tallman, M. S., & Levine, R. L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.210 · Cited by 125
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 125
Falini, B., Macijewski, K., Weiss, T., Bacher, U., Schnittger, S., Kern, W., Kohlmann, A., Klein, H., Vignetti, M., Piciocchi, A., et al. (2010) · Blood · doi:10.1182/blood-2009-08-240457 · Cited by 125
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
Parkin, B. L., Ouillette, P. D., Li, Y., Keller, J. A., Lam, C., Roulston, D., Li, C., Shedden, K., & Malek, S. N. (2012) · Blood · doi:10.1182/blood-2012-04-427039 · Cited by 123
Fraser, M. E., Berlín, A., Bristow, R. G., & van der Kwast, T. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.020 · Cited by 123
Ročková, V., Abbas, S., Wouters, B. J., Erpelinck-Verschueren, C. A. J., Beverloo, H. B., Delwel, R., van Putten, W. L. J., Löwenberg, B., & Valk, P. J. M. (2011) · Blood · doi:10.1182/blood-2011-02-334748 · Cited by 123
PRPF8 defects cause missplicing in myeloid malignancies
Kurtović-Kozarić, A., Przychodzen, B. P., Singh, J., Konarska, M. M., Clemente, M. J., Otrock, Z. K., Nakashima, M. O., Hsi, E. D., Yoshida, K., Shiraishi, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2014.144 · Cited by 123
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
Hermouet, S., Bigot‐Corbel, E., & Gardie, B. (2015) · Mediators of Inflammation · doi:10.1155/2015/145293 · Cited by 122
A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 122
Felsberg, J., Wolter, M., Seul, H., Friedensdorf, B., Goeppert, M., Sabel, M., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0647-4 · Cited by 121
Duncavage, E. J., Magrini, V. J., Becker, N., Armstrong, J. R., Demeter, R., Wylie, T., Abel, H., & Pfeifer, J. D. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.01.006 · Cited by 121
Self-citationGenetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Yang, B., Zhong, C., Peng, Y., Lai, Z., & Ding, J. (2010) · Cell Research · doi:10.1038/cr.2010.145 · Cited by 121
Cusan, M., Cai, S. F., Mohammad, H. P., Krivtsov, A. V., Chramiec, A. G., Loizou, E., Witkin, M. D., Smitheman, K. N., Tenen, D. G., Ye, M., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807024 · Cited by 120
Mitochondria as a target in cancer treatment
Liu, Y., & Shi, Y. (2020) · MedComm · doi:10.1002/mco2.16 · Cited by 120
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 119
TET Family Proteins: Oxidation Activity, Interacting Molecules, and Functions in Diseases
Lu, X., Zhao, B. S., & He, C. (2015) · Chemical Reviews · doi:10.1021/cr500470n · Cited by 118
Effects of informed consent for individual genome sequencing on relevant knowledge
Kaphingst, K., Facio, F. M., Cheng, M., Brooks, S. R., Eidem, H. R., Linn, A., Biesecker, B. B., & Biesecker, L. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01909.x · Cited by 118
Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia
Babushok, D. V., Perdigones, N., Perin, J. C., Olson, T. S., Ye, W., Roth, J. J., Lind, C., Cattier, C., Li, Y., Hartung, H. D., et al. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.007 · Cited by 118
Martelli, M. P., Pettirossi, V., Thiede, C., Bonifacio, E., Mezzasoma, F., Cecchini, D., Pacini, R., Tabarrini, A., Ciurnelli, R., Gionfriddo, I., et al. (2010) · Blood · doi:10.1182/blood-2009-08-238899 · Cited by 118
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
Nakajima, H., & Kunimoto, H. (2014) · Cancer Science · doi:10.1111/cas.12484 · Cited by 117
The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to ClinicPreprint
Mardis, E. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036269 · Cited by 118
Self-citationZhu, J., Xiong, Y., Zhang, Y., Wen, J., Cai, N., Cheng, K., Liang, H., & Zhang, W. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8810785 · Cited by 116
Human genetics and genomics a decade after the release of the draft sequence of the human genome
Naidoo, N., Yudi Pawitan, Y., Soong, R., Cooper, D. N., & Ku, C. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-577 · Cited by 117
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
Mutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424400112 · Cited by 115
Self-citationLin, X., Tang, W., Ahmad, S., Lü, J., Colby, C. C., Zhu, J., & Yu, Q. (2012) · Hearing Research · doi:10.1016/j.heares.2012.01.004 · Cited by 115
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 115
Genetic and epigenetic determinants of AML pathogenesis
Cai, S. F., & Levine, R. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.001 · Cited by 117
New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic
Foran, J. M. (2010) · Hematology · doi:10.1182/asheducation-2010.1.47 · Cited by 114
Shih, A. H., Meydan, C., SHANK, K. R., Garrett-Bakelman, F. E., Ward, P. S., Intlekofer, A. M., Nazir, A., Stein, E. M., Knapp, K. M., Glass, J. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1049 · Cited by 113
Rautenberg, C., Germing, U., Haas, R. R., Kobbe, G., & Schroeder, T. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010228 · Cited by 113
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 114
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
Non-syndromic hearing loss gene identification: A brief history and glimpse into the future
Vona, B., Nanda, I., Hofrichter, M. A. H., Shehata-Dieler, W. E., & Haaf, T. (2015) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2015.03.008 · Cited by 112
A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG
Pietrak, B., Zhao, H., Qi, H., Quinn, C. J., Gao, E. N., Boyer, J. G., Concha, N. O., Brown, K., Duraiswami, C., Wooster, R. F., et al. (2011) · Biochemistry · doi:10.1021/bi200499m · Cited by 112
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 111
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 111
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Park, S.-M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T. S., Taggart, J., Lu, Y., Deering, R. P., Hacohen, N., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78440 · Cited by 110
Our changing view of the genomic landscape of cancer
Bell, D. W. (2009) · The Journal of Pathology · doi:10.1002/path.2645 · Cited by 109
Metabolic recoding of epigenetics in cancer
Wang, Y., & Lei, Q. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0302-3 · Cited by 109
Wang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109
Targeting glucose metabolism in patients with cancer
Elf, S., & Chen, J. (2013) · Cancer · doi:10.1002/cncr.28501 · Cited by 108
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 108
Winkler, T., Fan, X., Cooper, J., Desmond, R. G., Young, D. J., Townsley, D. M., Scheinberg, P., Grasmeder, S., Larochelle, A., Desierto, M. J., et al. (2019) · Blood · doi:10.1182/blood.2019000478 · Cited by 108
The Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 108
Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia
Grimwade, D. J., & Mrózek, K. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.018 · Cited by 108
Itsumi, M., Inoue, S., Elia, A., Murakami, K., Sasaki, M., Lind, E. F., Brenner, D., Harris, I. S., Chio, I. I. C., Afzal, S., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.38 · Cited by 107
Suijker, J., Oosting, J., Koornneef, A., Struys, E. A., Salomons, G. S., Schaap, F. G., Waaijer, C. J. F., Wijers‐Koster, P. M., Bruijn, I. H. B., Haazen, L. C. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3723 · Cited by 106
Kato, Y., Jin, G., Kuan, C.-T., McLendon, R. E., Yan, H., & Bigner, D. D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.001 · Cited by 106
The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
Wang, T., Liang, J.-Y., Zhang, C., Xiong, Y., Guan, K., & Yuan, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1984-4 · Cited by 106
Banerji, V., Frumm, S. M., Ross, K. N., Li, L. S., Schinzel, A. C., Hahn, C. K., Kakoza, R. M., Chow, K. T., Ross, L., Alexe, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci46465 · Cited by 105
Independent prognostic variables in acute myeloid leukaemia
Smith, M. L., Hills, R. K., & Grimwade, D. J. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.10.002 · Cited by 105
Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
Kerr, D. A., Lopez, H. U., Deshpande, V., Hornicek, F. J., Duan, Z., Zhang, Y., Rosenberg, A. E., Borger, D. R., & Nielsen, G. P. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827ab703 · Cited by 105
Gröschel, S., Sanders, M. A., Hoogenboezem, R. M., Zeilemaker, A., Havermans, M., Erpelinck-Verschueren, C. A. J., Bindels, E. M., Beverloo, H. B., Döhner, H., Löwenberg, B., et al. (2014) · Blood · doi:10.1182/blood-2014-07-591461 · Cited by 105
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
Liu, A., Hou, C., Chen, H., Zong, X., & Zong, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00016 · Cited by 105
Next Generation DNA Sequencing and the Future of Genomic Medicine
Anderson, M. W., & Schrijver, I. (2010) · Genes · doi:10.3390/genes1010038 · Cited by 105
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Johannessen, T.-C. A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0141 · Cited by 105
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F., & Falini, B. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.11.001 · Cited by 104
Xu, J., Wang, Y., Dai, Y., Zhang, W., Zhang, W.-N., Xiong, S.-M., Gu, Z., Wang, K., Zeng, R., Zhu, C. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400150111 · Cited by 104
Solga, A. C., Pong, W. W., Keun-young Kim, A., Cimino, P. J., Toonen, J. A., Walker, J., Wylie, T., Magrini, V. J., Griffith, M., Griffith, O. L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.10.002 · Cited by 104
Self-citationBig science: The cancer genome challenge
Ledford, H. K. (2010) · Nature · doi:10.1038/464972a · Cited by 104
Massively parallel sequencing of ataxia genes after array-based enrichment
Hoischen, A., Gilissen, C., Arts, P., Wieskamp, N., van der Vliet, W., Vermeer, S., Steehouwer, M., de Vries, P., Meijer, R. P. P., Sequeiros, J., et al. (2010) · Human Mutation · doi:10.1002/humu.21221 · Cited by 103
Update on the types and usage of liquid biopsies in the clinical setting: a systematic review
Arneth, B. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4433-3 · Cited by 103
Cancer cell metabolism and the modulating effects of nitric oxide
Chang, C.-F., Diers, A. R., & Hogg, N. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.012 · Cited by 103
Kohlmann, A., Nadarajah, N., Alpermann, T., Grossmann, V., Schindela, S., Dicker, F., Roller, A., Kern, W., Haferlach, C., Schnittger, S., et al. (2013) · Leukemia · doi:10.1038/leu.2013.239 · Cited by 102
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
Dezern, A. E., Malcovati, L., & Ebert, B. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239083 · Cited by 102
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Kwok, D. W., Stevers, N. O., Etxeberría, I., Nejo, T., Cove, M. C., Chen, L. H., Jung, J., Okada, K., Lakshmanachetty, S., Gallus, M., et al. (2025) · Nature · doi:10.1038/s41586-024-08552-0 · Cited by 107
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
